Vaxcyte, Inc. (PCVX) Financial Ratios
9 years of historical data (2017–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
2.61
↓-27% vs avg
5yr avg: 3.58
30Y Low2.3·High4.9
ROE
↑
-25.6%
↓+15% vs avg
5yr avg: -30.1%
30Y Low-75%·High-20%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
PCVX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Vaxcyte, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $7.4B | $6.3B | $10.0B | $6.1B | $3.1B | $1.2B | $785M | — | — | — |
| Enterprise Value | $7.5B | $6.3B | $9.7B | $5.7B | $2.3B | $1.2B | $399M | — | — | — |
| P/E Ratio → | -9.14 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 2.61 | 2.34 | 3.02 | 4.92 | 3.26 | 4.35 | 2.27 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
PCVX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
PCVX Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -25.6% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -25.6% | -25.6% | -20.4% | -36.7% | -36.1% | -31.8% | -74.5% | — | — | -55.7% |
| ROA | -23.4% | -23.4% | -18.9% | -33.3% | -33.6% | -27.9% | -38.9% | -73.7% | -53.4% | -43.5% |
| ROIC | -24.2% | -24.2% | -22.1% | -69.6% | -94.5% | -81.2% | — | — | — | — |
| ROCE | -29.7% | -29.7% | -24.6% | -42.0% | -36.8% | -32.3% | -44.7% | -91.2% | -71.5% | -50.4% |
PCVX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $55M ($229M total debt minus $174M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.09 | 0.09 | 0.02 | 0.02 | 0.02 | 0.06 | — | — | — | 0.15 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.02 | -0.10 | -0.30 | -0.86 | -0.18 | -1.12 | — | — | -1.02 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -111741.50 | -14295.71 | -12744.29 | -1255.85 | -392.13 | — |
PCVX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Vaxcyte, Inc.'s current ratio of 7.91x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 7.54x to 7.91x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 7.91 | 7.91 | 12.75 | 7.54 | 23.26 | 8.93 | 8.30 | 5.58 | 9.93 | 8.53 |
| Quick Ratio | 7.91 | 7.91 | 12.75 | 7.54 | 23.26 | 8.93 | 8.30 | 5.58 | 9.93 | 8.53 |
| Cash Ratio | 7.59 | 7.59 | 12.46 | 7.43 | 22.98 | 8.57 | 8.24 | 5.34 | 9.85 | 8.48 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — |
PCVX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Vaxcyte, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $136M | $122M | $97M | $65M | $52M | $30M | $4M | $4M | $4M |
Peer Comparison
Compare PCVX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 PCVXYou | $7B | -9.1 | — | — | — | — | -25.6% | -24.2% | — |
 PFE | $143B | 18.5 | 10.3 | 15.8 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
 MRK | $281B | 15.6 | 10.8 | 22.8 | 72.0% | 36.2% | 36.9% | 22.0% | 1.7 |
 GSK | $102B | 6.9 | 8.6 | 13.3 | 72.4% | 25.5% | 39.4% | 22.1% | 1.7 |
 SNY | $102B | 18.2 | 10.8 | 10.1 | 72.3% | 13.6% | 10.4% | 5.5% | 2.3 |
 BNTX | $23B | -17.6 | — | 74.4 | 77.6% | -22.6% | -5.7% | -4.3% | — |
 NVAX | $2B | 3.6 | 2.6 | — | 93.7% | 50.1% | — | — | 0.4 |
 DVAX | $2B | 77.5 | 503.2 | 30.2 | 82.2% | -1.5% | 4.5% | -0.4% | 64.7 |
 IBRX | $8B | -19.4 | — | — | 99.3% | -226.0% | — | -235.9% | — |
 BRKR | $9B | -381.5 | 22.9 | 201.2 | 45.9% | 6.9% | -0.4% | 4.4% | 4.5 |
 TMO | $173B | 26.2 | 18.7 | 27.4 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 9 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
PCVX — Frequently Asked Questions
Quick answers to the most common questions about buying PCVX stock.
What is Vaxcyte, Inc.'s P/E ratio?
Vaxcyte, Inc.'s current P/E ratio is -9.1x. This places it at the 50th percentile of its historical range.
What is Vaxcyte, Inc.'s ROE?
Vaxcyte, Inc.'s return on equity (ROE) is -25.6%. The historical average is -40.1%.
Is PCVX stock overvalued?
Based on historical data, Vaxcyte, Inc. is trading at a P/E of -9.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.